About Oliver
Oliver is the founder of 20one Consulting Ltd, a consulting company based in Cambridge, England, focusing on the robustly proving the slowing and reversing of the fundamental aging processes in humans.
20one Consulting applies the following to achieve its mission:
Go to www.oliverzolman.com and www.longevity.school to learn more about my Longevity Level 1, 2, 3 evidence-based clinical protocol.
Our Cambridge UK based research company is working to prove age reduction from age 80 to 60 (25% mean organ age reduction with low organ age SD) by 2030, in all 78 organs.
1) I have created the 500+ Zolman Clocks to measure biological age in all 78 organ types across both genders, comprised of over 500 sub-clocks (multiple clocks per organ) to prove reversal of aging and prove n=1 LEV (longevity escape velocity) using my N=1 LEV equation.
2) I have written the Zolman Biological Age Marker (Z-BAM) criteria, with evergreen peer-review, 15 statistical criteria that markers must meet a minimum set of to be statistically and clinically valid, with no close comparison of such objective criteria made before to critically appraise biological age markers of any type (imaging, device or biosample based)
3) I created the Longevity Level 123 protocol to measure and reverse aging in all 78 organs using the most statistically rationale evidence based medicine (EBM) approach. This involves writing hundreds of novel experimental clinical guidelines covering every experimental longevity test and therapy, built on international gold-standard EBM principles such as AGREE2, IPDAS, N=1 CONSORT, GRADE, Cochrane Handbook of systematic reviews, NICE manual, etc. I have also extended beyond these gold-standards with my own standards for informed consent.
Level 123 protocol is designed using systems thinking to be unsurpassably systematic in every possible evidence based factor that can contribute to unwanted clinical or biomarker (imaging, device, biosample) outcomes
Level 1 = Proven to raise mean lifespan by 2+ years in 50%+ of people and stack their effects: 6 components: CRON, AHEI-2010 diet, Exercise, BMI, Alcohol, Smoking
Level 2 = Non-age related: 13 categories of non-age related causes of unwanted clinical outcomes
Level 3 = Measure 500+ Zolman Clocks, other clocks, 78 organ ages, Level 3 tests and therapies experimental clinical guidelines
4) I created Longevity School to teach Longevity 123 protocol and how to measure the 78 organ clocks at research grade standard. This allows clinicians and innovators to become their own rejuvenation research groups by using gold-standard markers with gold-standard methodology, and see which organs or markers they can rejuvenate with on label, off label or unlicensed therapies.
Longevity School is an online platform with native mobile apps, desktop apps, video content that adheres to Medical Education gold-standards, evergreen peer-review and conflict of interest statements. Longevity School provides certification and revalidation in Longevity Escape Velocity Medicine (LEVMED) Speciality Training, first published in the peer-reviewed PubMed listed journal Rejuvenation Research February edition in 2018 and presented at the 2018 the Undoing Aging Conference.
5) I created the field of competitive longevity, publishing the first Rejuvenation Leaderboards and using a rationale and evidence based points system based on the 500+ Zolman Component Clocks to rank individuals. I further expanded this concept to sub-leaderboards for specific organ rejuvenation.
6) I have also created many multi-organ clocks that provide a systemic view of aging processes that will affect many organs, these also need to be reversed.
7) I have created the first organ age heatmaps which show biological age heatmaps within organs, showing which parts of one's individual organs are aging fastest and causing the overall organ to be older.
8) I actively call out pseudomedicine, pseudo-aging tests, pseudo aging therapies, sub-par practice and objectively irrational thinking using evidence based medicine principles and peer-reviewed references to back up my claims. This includes the concept of 'no guideline --> no experimental test or therapy'.
9) I have written the first experimental clinical guidelines and pharmacokinetic pharmacodynamic translational models for all wild type mouse lifespan studies interventions, e.g. Rapamycin, Alfatradiol, NGDA, AAV/CMV HTERT/Follistatin/klotho etc (50+). I have ranked every wild type mouse lifespan study by effect size on maximal lifespan and this is a core part of longevity school and level 3 therapy strategy.
His clientele include Bryan Johnson, founder of Braintree-Venmo (sold to Paypal for $800M), Kernel and OS Fund, and with Oliver created Project Blueprint, documenting his work with Oliver to maximally reverse the quantified biological age of all of his organs using the 500+ Zolman Clocks and Level 123 protocol. Bryan and Oliver's parents are the first people to go through the Longevity Level 123 protocol, quantify the biological age of all 78 organs using Zolman Clocks and maximally reverse them using Level 123 therapies experimental clinical guidelines.
Qualifications
Oliver earned his M.B.B.S. from King's College London, England (equivalent to the US M.D.)
First Class Honours BSc in Regenerative Medicine, Innovation Technology & Biology of Aging.
Visiting Fellowship in Evidence Based Medicine, at the University of Sydney
Cambridge University Judge Business School Accelerator Program
Cambridge University Medical Education Masters to be started in 2023
Disclosures & disclaimer
Oliver is an advisor to the companies Dante Labs, Front Seat Capital, FiveAlarmBio and AgeCurve,
Why did I not proceed with NHS consultancy training after graduating?
Whilst I received interviews for the Academic Foundation Program at Oxford and Severn Foundation Schools, in 2018-19, as well as an F1 job offer, I decided to not go ahead with F1 training or further, or to to activate my UK registration or license.
This is because since the beginning of medical school I have been planning to manage systems at scale, and individual clinical practise, whilst providing further clinical gestalt, comes at the huge opportunity cost of not being able to develop knowledge, skills and network outside of standard clinical medicine that are needed to transition society to a post-aging society. Whilst these knoweldge and skills overlap with Old-age/Geriatric medicine, General Practice, Pharmacetical Medicine, Lifestyle Medicine and Oncology somewhat - on my assessment there is ultimately no medical speciality training route in the NHS for me that would provide me the highest probability of helping society cure age-related diseases and fundamental aging pathology as soon as possible.
As a result, I chose to undertake the following strategy:
Supporting clinicians to practise Longevity Level 1, 2, 3 evidence-based medicine
- Writing gold-standard clinical practice evidence-based guidelines for Longevity Level 1, 2, 3 medicine (AGREE-II, PRISMA etc.) (e.g. see www.longevity.school/methodology for an example of how content is created)
- Developing scalable ways to train licensed clinicians in gold standard evidence-based Longevity Level 1, 2, 3 medicine pan-jurisdictionally
- Developing supporting clinical and clinical research software to enable clinicians to practise Longevity Level 1, 2, 3 medicine more easily (given current electronic health record software is inadequate for this)
- Managing ethical approval, off label prescribing, unlicensed prescribing and clinical research projects in patients to develop high quality evidence of safety and efficacy (ultimately to generate high quality evidence of multi-decade reversal of high-quality aging biomarkers in all organs in clients)
- Involving clinicians in the research process to develop new Longevity Level 3 therapies
Supporting patients to make truly informed Longevity related decisions and implement them
- Creating gold-standard international patient decision aid (IPDAS) compliant patient decision aids on key decision longevity decision topics patients face
- Creating software and resources for patients to manage their longevity
- To help patients avoid scams and excessive risk
- Involving patients in the research process to develop new Longevity Level 3 therapies
Supporting the development of Longevity Level 3 therapies
- Supporting the development of new Longevity Level 3 tests and therapies through financing, investor awareness, regulatory advice, patent strategy, preclinical & phase 1 - 4 trial design etc.
- Integrating these new Longevity Level 3 therapies into clinical practice rapidly, through developing clinical guidelines for these therapies and integrateing these into the Longevity Level 1, 2, 3 medicine clinical guidelines and practitioner/clinic network
Whilst I may provide "informational/educational advice" rather than medical advice to people - i.e. these are the studies I found from a systematic review of the literature on PubMed for your condition and these are the key points or references I suggest you should discuss with your licensed doctor based on my experience, caveated with a lengthy disclaimer, I am not able to provide medical advice, having no license or registration to practise in any jurisdiction. See our medical disclaimer.
About Us
Contact Us
oliver@
My Account
Copyright 2016-2023 20one Consulting Ltd.
Cambridge, UK
Legal
Products and Services do not provide medical advice. Do not make any changes to your health behaviours without consulting your licensed clinicians first. See the medical disclaimer within the terms and conditions.
Oliver Zolman does not give medical advice. The contents on this site and his related Products & Services are for health informational purposes only, not medical advice.